Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025
Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025
kymera therapeutics宣佈將在TH2驅動的過敏和特應性疾病中展示KT-621的臨床前數據，該公司計劃在2024年下半年啓動1期臨床試驗，預計在2025年上半年公佈數據
Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025
kymera therapeutics宣佈將在TH2驅動的過敏和特應性疾病中展示KT-621的臨床前數據，該公司計劃在2024年下半年啓動1期臨床試驗，預計在2025年上半年公佈數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間